| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00428-016-1905-1 |
| P698 | PubMed publication ID | 26832731 |
| P50 | author | Ede Birtalan | Q56811247 |
| Bianka Gurbi | Q87203128 | ||
| P2093 | author name string | Tibor Krenács | |
| István Peták | |||
| Diána Brauswetter | |||
| Nóra Meggyesházi | |||
| László Tamás | |||
| Kornél Dános | |||
| Éva Fruzsina Félegyházi | |||
| P2860 | cites work | C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell | Q38212355 |
| Human papillomavirus and Epstein Barr virus in head and neck carcinomas: suggestions for the new WHO classification | Q38255620 | ||
| Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification | Q38370754 | ||
| Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas | Q38388575 | ||
| Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer | Q39503071 | ||
| Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus | Q42674338 | ||
| Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas | Q46127298 | ||
| Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status | Q49215383 | ||
| Differential biomarker expression in head and neck cancer correlates with anatomical localization. | Q51871346 | ||
| PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients. | Q54287725 | ||
| Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. | Q54341358 | ||
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study | Q57152185 | ||
| PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | Q58813317 | ||
| Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma | Q58827057 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study | Q27851592 | ||
| EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study | Q27851683 | ||
| Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers | Q27852227 | ||
| Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement | Q27852650 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 | ||
| COSMIC: exploring the world's knowledge of somatic mutations in human cancer | Q29615725 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma | Q31096247 | ||
| Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance | Q34161089 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| Targeting MET Amplification as a New Oncogenic Driver. | Q34309927 | ||
| Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
| PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. | Q35068192 | ||
| Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients | Q35926926 | ||
| Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma | Q35994228 | ||
| EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study | Q36584164 | ||
| Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients | Q36755257 | ||
| Cetuximab: its unique place in head and neck cancer treatment | Q36880604 | ||
| The biological role of HGF-MET axis in tumor growth and development of metastasis | Q36992086 | ||
| MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. | Q37321772 | ||
| MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma | Q37490555 | ||
| MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 | ||
| The molecular biology of head and neck cancer | Q37821229 | ||
| Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma | Q37990112 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 579-587 | |
| P577 | publication date | 2016-01-29 | |
| P1433 | published in | Virchows Archiv | Q19059548 |
| P1476 | title | Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma | |
| P478 | volume | 468 |
| Q93168398 | Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma |
| Q42026346 | Genetic and epigenetic characterization of the tumors in a patient with a tongue primary tumor, a recurrence and a pharyngoesophageal second primary tumor |
| Q36097570 | Genomic Alteration in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Inferred from Karyotyping, Molecular Cytogenetics, and Array Comparative Genomic Hybridization. |
| Q57472125 | High expression of TMEM40 contributes to progressive features of tongue squamous cell carcinoma |
| Q52607160 | Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. |
| Q90596397 | NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer |
| Q93026726 | Neutrophils infiltration and its correlation with human papillomavirus status in the oral squamous cell carcinoma |
| Q64238086 | Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma |
Search more.